Changhe Ding

Prof. Dr. Changhe Ding


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2019 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
CDChanghe Ding
Changhe Ding
XWXiang Wang
Xiang Wang
MLMengxing Li
Mengxing Li

1 October 2018 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
CDChanghe Ding
Changhe Ding
MLMengxing Li
Mengxing Li
YHYuqi Hu
Yuqi Hu

10 February 2023 in Molecules
Verified
Journal Article
Open access
PDF file
FXFugang Xiao
Fugang Xiao
MGMenglin Gu
Menglin Gu
YZYaoxuan Zhang
Yaoxuan Zhang
YXYaodong Xian
Yaodong Xian
YZYaotian Zheng
Yaotian Zheng
DWDe-Guo Wang
De-Guo Wang
Food adulteration is a serious problem all over the world. Establishing an accurate, sensitive and fast detection method is an important part of identifying food adulteration. Herein, a sequence-specific ladder-shape melting temperature isothermal amplification (LMTIA) assay was reported to detect soybean-derived components using proofreading enzyme-mediated probe cleavage (named Proofman), which could realize real-time and visual detection without uncapping. The results showed that, under the optimal temperature of 57 °C, the established Proofman–LMTIA method for the detection of soybean-derived components in dairy products was sensitive to 1 pg/μL, with strong specificity, and could distinguish soybean genes from those of beef, mutton, sunflower, corn, walnut, etc. The established Proofman–LMTIA detection method was applied to the detection of actual samples of cow milk and goat milk. The results showed that the method was accurate, stable and reliable, and the detection results were not affected by a complex matrix without false positives or false negatives. It was proved that the method could be used for the detection and identification of soybean-derived components in actual dairy products samples.

10 May 2024 in Foods
Verified
Journal Article
Open access
PDF file
NWNan Wang
Nan Wang
CDChanghe Ding
Changhe Ding
YXYingying Xie
Yingying Xie
JMJun Meng
Jun Meng
XFXing Fan
Xing Fan
ZJZhengqiang Jiang
Zhengqiang Jiang
Chickpea has significant benefits as an adjuvant treatment for type 2 diabetes mellitus (T2DM). The properties of chickpea resistant starches (RSs) and their abilities to reduce T2DM symptoms and control intestinal flora were investigated. The RS content in citrate-esterified starch (CCS; 74.18%) was greater than that in pullulanase-modified starch (enzymatically debranched starch (EDS); 38.87%). Compared with those of native chickpea starch, there were noticeable changes in the granular structure and morphology of the two modified starches. The CCS showed surface cracking and aggregation. The EDS particles exhibited irregular layered structures. The expansion force of the modified starches decreased. The CCS and EDS could successfully lower blood glucose, regulate lipid metabolism, lower the levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C), reduce the expressions of interleukin-6 (IL-6) and interleuki n-10 (IL-10), and decrease diabetes-related liver damage. Moreover, the CCS and EDS altered the intestinal flora makeup in mice with T2DM. The abundance of Bacteroidota increased. Both types of chickpea RSs exhibited significant hypoglycaemic and hypolipidaemic effects, contributing to the reduction in inflammatory levels and the improvement in gut microbiota balance.

19 November 2025 in Applied and Environmental Microbiology
Verified
Journal Article
Open access
YMYue Meng
Yue Meng
LBLu-Jia Bai
Lu-Jia Bai
JMJun Meng
Jun Meng
CDChanghe Ding
Changhe Ding
JXJun Xi
Jun Xi
Obesity has emerged as a significant global health threat. In this study, we investigated the anti-obesity properties of Clostridium butyricum B-3, a strain noted for its high butyric acid production. This strain was administered to mice on a high-fat diet (HFD) to assess its potential anti-obesity effects. Our findings indicate that three different dosages of C. butyricum B-3 significantly ( P < 0.05) mitigated excessive weight gain and ameliorated kidney and liver damage in HFD mice. A medium dose (10 7 CFU/day) of C. butyricum B-3 markedly reduced levels of total cholesterol, triglycerides and low-density lipoprotein cholesterol, and elevated levels of high-density lipoprotein cholesterol in HFD mice. Additionally, this dosage lowered serum levels of inflammatory cytokines, including IL-6, IL-10, and TNF-α. Furthermore, treatment with C. butyricum B-3 enhanced the diversity and relative abundance of gut microbiota in HFD-fed mice. Notably, the gut microbiota composition of the high-dose (10 8 CFU/day) group closely resembled that of mice fed a normal diet. C. butyricum B-3 also significantly increased the concentrations of acetic acid, propionic acid, and butyric acid in the gut. In summary, C. butyricum B-3 demonstrated significant anti-obesity effects and the ability to regulate intestinal microbiota in HFD mice. IMPORTANCE: Obesity represents one of the most severe global health challenges of our time. Clostridium butyricum has recently been recognized as a next-generation probiotic with considerable potential for applications in intestinal health, metabolic diseases, and neuroprotection. Our research focused on a specific strain of C. butyricum known for its anti-obesity effects, which displayed robust capabilities in mitigating obesity and regulating intestinal flora. This strain holds significant promise for development in anti-obesity nutritional products and pharmaceuticals.

1 January 2026 in Foods
Verified
Journal Article
Open access
PDF file
NWNan Wang
Nan Wang
CDChanghe Ding
Changhe Ding
JGJun Gao
Jun Gao
LDLingguang Du
Lingguang Du
DZDongge Zheng
Dongge Zheng
HLHaiwei Lou
Haiwei Lou
Helicobacter pylori infection is a primary cause of gastritis and gastric ulcers. It is crucial to find alternative therapies for H. pylori infection due to the significant side effects of current antibiotics. Heyndrickxia coagulans is an ideal probiotic due to its functionality and stability in production and storage. This study explored the anti-bacterial effects of H. coagulans BHE26 in vitro and in vivo. H. coagulans BHE26 showed notable tolerance to simulated gastric juice (pH 3.0) and 1% bile salts, highlighting its potential suitability for gastrointestinal survival. H. coagulans BHE26 was resistant to ceftriaxone but sensitive to penicillin, ampicillin, erythromycin, gentamicin, ciprofloxacin, ceftriaxone, lincomycin, tetracycline and chloramphenicol. These characteristics showed that H. coagulans BHE26 is a potential probiotic bacterium. In vitro assays demonstrated that H. coagulans BHE26 inhibited H. pylori, reduced urease activity, and displayed notable auto-aggregation and co-aggregation abilities. In vivo, administration of H. coagulans BHE26 alleviated H. pylori-induced gastric mucosal damage, significantly lowered serum anti-bacterial IgG levels, and modulated gastric microbiota composition, including an increase in Turicibacter and a decrease in Lactobacillus abundance. These results indicate that H. coagulans BHE26 alleviated H. pylori-induced inflammation, offering a novel therapeutic strategy against H. pylori infection.